CTOs on the Move

Healthlogix

www.hlxusa.com

 
Healthlogix is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.hlxusa.com
  • 99 Cherry Hill Rd
    Parsippany, NJ USA 07054
  • Phone: 973.401.1600

Executives

Name Title Contact Details

Similar Companies

Aspyrian Therapeutics

Aspyrian Therapeutics is a new start-up located in San Diego (California, USA) that focuses on developing novel targeted therapies for Oncology, Inflammation, and Pain. Aspyrian Therapeutics and its collaborators are developing novel cancer targeted therapies based on proprietary technologies that achieve highly specific and tumor restricted anticancer activity. Tumor specific action serves to avoid damage to healthy organs for enhanced anticancer activity and increased safety profile. Aspyrian Therapeutics has secured the exclusive license from the National Cancer Institute for a new Antibody Conjugate Technology: Near-infrared Photoimmunotherapy (PIT). PIT permits highly efficient and selective ablation of tumor cells while sparing damage to critical structures adjacent to the tumor.

Southlake Orthopaedics

LESS PAIN More Living At Southlake Orthopaedics, you can trust us to provide personalized and compassionate care, utilizing the most advanced medical technology available. Our clinics are home to the expertise of physicians in every orthopaedic special...

Fastrack Pharmaceuticals

Fastrack Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RxAdvance

RxAdvance, a national full service PBM, leverages the disruptive Collaborative PBM Cloud™ to manage standard and specialty drug benefits with unmatched regulatory compliance and transparency. In addition, RxAdvance is willing to share global pharmacy risk, avoidable drug-impacted medical risk, and bundled episode specialty pharmacy risk, standing shoulder-to-shoulder with plan sponsors as a true accountable partner. This risk model has never been offered by any other PBM.